Back to All Collaborations

TransCelerate Biopharma

Active Since: 2012

Multi-Company Partnership

Contributing to SDGs…

TransCelerate is a nonprofit organization with the mission to collaborate across the biopharmaceutical industry to increase the efficiency, effectiveness and quality of the medicine development process.

MEMBER COMPANIES

PARTNER ORGANISATIONS

  • Global NGOs

    TransCelerate

  • Professional and trade associations

    ACRO CRO Forum

    Contribution

    The Forum provides an opportunity for subject matter experts (SMEs) from ACRO members and participating non-member companies to engage colleagues, provide industry input to TransCelerate workstreams and report back on TransCelerate developments, helping to inform member company perspectives and strategies

Objectives

  • Accelerating and simplifying the drug development processes through collaboration.

The biopharmaceutical industry strives to ensure patient wellness and safety by producing new medicines that are safe and effective. However, the development of these medicines can be hampered by inefficiencies and challenges throughout the process of conducting clinical studies and applying for and receiving regulatory approval to make the medicine available to patients.

Through TransCelerate, participants in these processes collaboratively develop tools and procedures, clarify and harmonize standards and improve the patient experience so that clinical trials can occur more efficiently, results can be reported more accurately, regulatory reviews can be streamlined and patients around the world can have access to safe and effective medicines more quickly. TransCelerate has a portfolio of nearly 40 initiatives focused on specific aspects of these processes.

SDGs THE PARTNERSHIP CONTRIBUTES TO

SDG 3: Good Health and Wellbeing

SDG 9: Industry Innovation and Infrastructure

SDG 17: Partnerships for the Goals 

RESULTS & MILESTONES

Since its founding in 2012, the TransCelerate partnership has developed and published multiple tools to aid in the efficient and effective development of new medicines. It has also developed shared knowledge bases on topics such as communication with clinical trial participants, investigator qualification and safety monitoring.

ADDITIONAL INFORMATION

FURTHER READING